Literature DB >> 8692986

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.

J Balzarini1, A Karlsson, S Aquaro, C F Perno, D Cahard, L Naesens, E De Clercq, C McGuigan.   

Abstract

So324 is a 2',3'-dideoxy-2',3'-didehydrothymidine-5'-monophosphate (d4T-MP) prodrug containing at the phosphate moiety a phenyl group and the methylester of alanine linked to the phosphate through a phosphoramidate linkage. So324 has anti-HIV activity in human CEM, MT4, and monocyte/macrophage cells that is superior to that of d4T. In contrast to d4T, So324 is also able to inhibit HIV replication in thymidine kinase-deficient CEM cells. After uptake of So324 by intact human lymphocytes, d4T-MP is released and subsequently converted intracellularly to d4T-TP. In addition, accumulation of substantial amounts of a novel d4T derivative has been found. This d4T metabolite has been characterized as alaninyl d4T-MP. The latter metabolite accumulates at approximately 13- to 200-fold higher levels than d4T-TP depending the experimental conditions. Alaninyl d4T-MP should be considered as an intra- and/or extracellular depot form of d4T and/or d4T-MP. These findings may explain the superior anti-retroviral activity of So324 over d4T in cell culture.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692986      PMCID: PMC38977          DOI: 10.1073/pnas.93.14.7295

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.

Authors:  Z Hao; D A Cooney; D Farquhar; C F Perno; K Zhang; R Masood; Y Wilson; N R Hartman; J Balzarini; D G Johns
Journal:  Mol Pharmacol       Date:  1990-02       Impact factor: 4.436

2.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

Authors:  G Ahluwalia; D A Cooney; H Mitsuya; A Fridland; K P Flora; Z Hao; M Dalal; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

3.  Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.

Authors:  J Balzarini; C F Perno; D Schols; E De Clercq
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

4.  Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.

Authors:  J Balzarini; P Herdewijn; E De Clercq
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

5.  Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues.

Authors:  J Balzarini; M Baba; R Pauwels; P Herdewijn; E De Clerq
Journal:  Biochem Pharmacol       Date:  1988-07-15       Impact factor: 5.858

6.  Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.

Authors:  M A Johnson; A Fridland
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

7.  Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.

Authors:  C McGuigan; D Cahard; H M Sheeka; E De Clercq; J Balzarini
Journal:  J Med Chem       Date:  1996-04-12       Impact factor: 7.446

8.  Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

Authors:  Z Hao; D A Cooney; N R Hartman; C F Perno; A Fridland; A L DeVico; M G Sarngadharan; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

9.  Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase.

Authors:  C McGuigan; P Bellevergue; H Sheeka; N Mahmood; A J Hay
Journal:  FEBS Lett       Date:  1994-08-29       Impact factor: 4.124

10.  The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

Authors:  J Balzarini; G J Kang; M Dalal; P Herdewijn; E De Clercq; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1987-07       Impact factor: 4.436

View more
  16 in total

1.  Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.

Authors:  Fatih M Uckun; Sharon Pendergrass; T K Venkatachalam; Sanjive Qazi; Douglas Richman
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Thiophene-expanded guanosine analogues of Gemcitabine.

Authors:  Zhe Chen; Therese C Ku; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem Lett       Date:  2015-07-30       Impact factor: 2.823

3.  Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3.

Authors:  Pawel Bieganowski; Preston N Garrison; Santosh C Hodawadekar; Gerard Faye; Larry D Barnes; Charles Brenner
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

Authors:  Gabriel Birkus; Ruth Wang; Xiaohong Liu; Nilima Kutty; Holly MacArthur; Tomas Cihlar; Craig Gibbs; Swami Swaminathan; William Lee; Martin McDermott
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

6.  In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters.

Authors:  H Uchida; E N Kodama; K Yoshimura; Y Maeda; P Kosalaraksa; V Maroun; Y L Qiu; J Zemlicka; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate.

Authors:  Heng Song; Rachel Johns; George W Griesgraber; Carston R Wagner; Cheryl L Zimmerman
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

8.  Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191.

Authors:  Gabriel Birkus; Nilima Kutty; Christian R Frey; Riri Shribata; Tsuifen Chou; Carston Wagner; Martin McDermott; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

9.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

Review 10.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.